No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Johannes Griss; Gudrun Ratzinger; Julia Tatjana Maul; Wolfgang Weger; Diamant Thaçi; José Manuel Carrascosa; Constanze Jonak

doi:10.1002/ski2.263

No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Johannes Griss, Gudrun Ratzinger, Julia Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa, Constanze Jonak^*

^*Corresponding author for this work

Institute of Inflammation Medicine

Original language	English
Article number	e263
Journal	Skin Health and Disease
Volume	3
Issue number	5
DOIs	https://doi.org/10.1002/ski2.263
Publication status	Published - 10.2023

Funding

We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. This publication was funded by Almirall R&D, Barcelona, Spain.

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

2.22-19 Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ski2.263

Cite this

Griss, J., Ratzinger, G., Maul, J. T., Weger, W., Thaçi, D., Carrascosa, J. M., & Jonak, C. (2023). No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies. Skin Health and Disease, 3(5), Article e263. https://doi.org/10.1002/ski2.263

@article{2d8a6ab36e9447a8bd9a5f9111253df5,

title = "No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies",

author = "Johannes Griss and Gudrun Ratzinger and Maul, \{Julia Tatjana\} and Wolfgang Weger and Diamant Tha{\c c}i and Carrascosa, \{Jos{\'e} Manuel\} and Constanze Jonak",

note = "Funding Information: We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. This publication was funded by Almirall R\&D, Barcelona, Spain. ",

year = "2023",

month = oct,

doi = "10.1002/ski2.263",

language = "English",

volume = "3",

journal = "Skin Health and Disease",

issn = "2690-442X",

publisher = "Oxford University Press",

number = "5",

}

Griss, J, Ratzinger, G, Maul, JT, Weger, W, Thaçi, D, Carrascosa, JM & Jonak, C 2023, 'No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies', Skin Health and Disease, vol. 3, no. 5, e263. https://doi.org/10.1002/ski2.263

No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies. / Griss, Johannes; Ratzinger, Gudrun; Maul, Julia Tatjana et al.
In: Skin Health and Disease, Vol. 3, No. 5, e263, 10.2023.

Research output: Journal Articles › Letters › peer-review

TY - JOUR

T1 - No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis

T2 - Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

AU - Griss, Johannes

AU - Ratzinger, Gudrun

AU - Maul, Julia Tatjana

AU - Weger, Wolfgang

AU - Thaçi, Diamant

AU - Carrascosa, José Manuel

AU - Jonak, Constanze

N1 - Funding Information: We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. This publication was funded by Almirall R&D, Barcelona, Spain.

PY - 2023/10

Y1 - 2023/10

UR - https://www.scopus.com/pages/publications/85163654379

U2 - 10.1002/ski2.263

DO - 10.1002/ski2.263

M3 - Letters

AN - SCOPUS:85163654379

SN - 2690-442X

VL - 3

JO - Skin Health and Disease

JF - Skin Health and Disease

IS - 5

M1 - e263

ER -

No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Funding

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Cite this